ADPKD evidence summary for clinicians

Tolvaptan remains the best-supported disease-modifying therapy

for selected adults at risk of rapid progression.

• Core evidence: TEMPO 3:4 (PMID23121377), REPRISE (PMID29105594), KDIGO 2025 (PMID39848759, PMID39848746), Lancet 2026 review (PMID41771281).
• Practical caution: liver monitoring, aquaretic burden, and careful patient selection still limit real-world uptake.

Risk-stratified care is the current management backbone.

• Guideline anchors: KDIGO 2025, KDOQI U.S. commentary (PMID41864657), ACR imaging guidance (PMID41823938).
• Use MRI-based TKV/prognostic frameworks where available, plus BP control, sodium reduction, CKD-safe care, and complication surveillance.

Guideline-concordant care still depends on local access and logistics.

• New CARI regional commentary on KDIGO 2025 (PMID42011799) highlights real-world implementation barriers, especially access/public-subsidy constraints for recommended genetic testing and tolvaptan plus rural/remoteness equity issues.
• Practical use: before assuming guideline-concordant pathways are available, check local reimbursement, genetics access, monitoring capacity, and travel burden.
• Limitation: commentary only, not new efficacy data.

Hydration is supportive, not proven disease modification.

• Best human test: 3-year RCT of prescribed high water intake did not slow htTKV growth versus ad libitum intake (PMID38319283).
• Use individualized hydration framing, not hype.

Risk stratification beyond imaging alone

got a useful validation bump.

• A now PubMed-indexed *Kidney International Reports* prognostic study found that adding **KFRE** to **Mayo Imaging Classification / TKV-based staging** improved prediction of kidney replacement therapy or 40% eGFR decline in ADPKD patients with **eGFR <60** (PMID42027549; DOI10.1016/j.ekir.2026.106489).
• Clinical use: helps refine who looks higher risk once patients are already phenotyped by imaging, especially in later CKD stages.
• Limitation: prognostic validation only. It supports smarter counseling/monitoring and treatment-timing discussions, not a new therapy.

Structured genetic diagnosis workflow

improved.

• Systematic review supports targeted NGS-first testing, with MLPA/LR-PCR as adjuncts for difficult PKD1/copy-number cases (PMID41938343).
• Clinical use: better classification, family counseling, and trial matching, not treatment efficacy.

Diet-quality counseling

gained a modest ADPKD-specific vascular-support signal.

• In adults with CKD G2-G4 ADPKD, higher Mediterranean-diet adherence was associated with higher nitric oxide and lower endothelin-1, consistent with better endothelial-function profile (PMID41897382).
• Clinical use: reinforces Mediterranean-style diet quality as a reasonable supportive counseling option for cardiometabolic and vascular health.
• Limitation: small cross-sectional biomarker study only, with no htTKV, eGFR-slope, or outcome proof.

Patient-reported burden measurement

got more systematic support.

• A new *Clinical Kidney Journal* systematic review found that HRQOL in ADPKD worsens with CKD stage progression, dialysis carries the lowest physical-health burden profile, and transplant improves but does not normalize HRQOL (DOI10.1093/ckj/sfag116).
• Clinical use: supports being more deliberate about symptom-burden review and about choosing kidney- or ADPKD-specific PROMs when trying to track lived burden, not just lab/imaging progression.
• Limitation: systematic review of a small heterogeneous PROM literature, not treatment-efficacy evidence.

Tolvaptan urinary-burden tracking

now has a more usable disease-specific tool.

• A 2026 *Advances in Therapy* content-validation study developed **PKD Daily** (PMID41806278), a hybrid smartphone diary for **dose timing, overnight urination, daytime urgency/frequency, and daily urinary-impact tracking** in adults taking tolvaptan.
• Clinical use: gives clinicians a more structured way to review aquaretic burden, dose timing, and tolerability instead of relying on vague recall during follow-up.
• Limitation: this is a usability/content-validation paper, not evidence that the diary improves adherence, quality of life, or kidney outcomes.

Environmental-risk framing

gained a cautious observational signal.

• Large PKD cohort linked higher PM2.5 exposure with steeper eGFR decline (PMID41979893).
• Limitation: not genotype-resolved to pure ADPKD, observational only, not proof that exposure reduction slows disease.

Weight-risk counseling

picked up another low-hype vascular/metabolic signal.

• In early-stage non-diabetic ADPKD, overweight and obesity were independently associated with lower MRI-measured renal blood flow after adjustment for blood pressure, eGFR, and htTKV (PMID41911082).
• A separate small Bologna real-world cohort with MRI-based body-composition measurement found higher **visceral adipose tissue** was independently associated with **faster eGFR decline** over about 31 months, even with some tolvaptan exposure in the cohort (PMID41948116).
• Clinical use: this modestly strengthens body-weight and cardiometabolic counseling as part of supportive care and sharpens the point that **central adiposity may matter more than BMI alone**.
• Limitation: both signals remain observational; the VAT study is small and letter-format, so this still does **not** prove that intentional weight loss, VAT reduction, or altered tolvaptan dosing changes renal outcomes in ADPKD.

Specialized procedural management

got a more cautionary advanced-disease update.

• A new larger retrospective cohort of **124 native nephrectomy episodes** in symptomatic ADPKD (PMID42012776) found **58.9% overall** and **25.0% major** perioperative complication rates, with **simultaneous bilateral nephrectomy** carrying the heaviest burden.
• Minimally invasive surgery was feasible in selected smaller-kidney cases but was **not independently associated with lower complication risk** after adjustment for case complexity.
• Earlier transplant-time retroperitoneoscopic nephrectomy data (PMID41972228) still suggest niche benefits in expert centers, but this broader cohort **weakens any low-burden assumption** around nephrectomy planning.
• A separate autopsy series found portal vein/IVC thrombosis in 4 of 10 ADPKD cases, with larger kidney weight suggesting compression-related venous stasis in massively enlarged kidneys (PMID41649706).
• Clinical use: strengthens symptom-driven case selection, pre-op risk review, and careful timing around transplantation, not broad screening or routine nephrectomy.
• Limitation: non-randomized, center-specific data with referral and technique-selection bias.

SGLT2 inhibitors

have stronger observational momentum but still are not guideline-ready for ADPKD progression slowing.

• Signals: small crossover dapagliflozin study (PMID40303212), TriNetX cohort with lower dialysis initiation (PMID41853136).
• Constraint: randomized endpoint-bearing confirmation still pending, including STOP-PKD (NCT07280585). A separate phase-2 empagliflozin physiology study (NCT06435858) is useful for mechanistic and tolerability mapping, not efficacy proof.

Metabolic/weight-pathway approaches

remain plausible but unproven.

• Trials to watch: tirzepatide (NCT06582875), bempedoic acid (NCT07282821), tamibarotene (NCT06289998), HCT add-on to tolvaptan (NCT05373264).

Diet and early-risk-management watchlists

are a little more concrete now.

• Di-PKD (NCT06786260) will test a 12-month targeted dietary intervention against usual diet with TKV change as the primary endpoint.
• Family study NCT07260071 is recruiting adolescents at risk of ADPKD to define hypertension prevalence with MRI and genetic testing support.
• Both are useful official watch items for lifestyle and early-management planning, but neither changes care standards today.

Endothelial-dysfunction / homocysteine biomarker tracking

is now a cleaner official watch item.

• Newly normalized ClinicalTrials.gov cohort **NCT05193981** is prospectively following early ADPKD patients with MRI-based **htTKV**, **renal blood flow**, peripheral endothelial-function testing, and homocysteine-related metabolite panels.
• Why it matters: it directly tests whether the emerging **microvascular/endothelial dysfunction** story seen in recent translational work (for example PMID41643210) holds up in a structured human prospective cohort.
• Why it still does **not** change practice: this is a biomarker/prognostic study, not a treatment trial, so it should sharpen risk biology and future target prioritization, not be mistaken for efficacy evidence.

Serum osmolality may be prognostic, while prescribed high water intake still lacks disease-modifying proof

(PMID41678280 vs PMID38319283).

SGLT2 hypothesis is stronger than before, but guideline caution is still justified

(PMID41853136 vs KDIGO 2025).

Pipeline momentum remains real, but most non-tolvaptan paths still lack outcome-grade human evidence.